As promised, here is a high level review of the manufacturing contracts between US DOD and Moderna.
Part 1 of this article which talks about Moderna’s R&D contract can be found here.
To recall, Moderna’s injection, mRNA-1273 is co-owned with the US Government, as the company has been funded by the defense research grants for years and also received intellectual property transfers from the US Government, in addition to preclinical and clinical research work conducted for Moderna by the NIH Vaccine Research Center. The NIH and Moderna each have a separate Investigational New Drug number for this product.
- “Vaccine” contract and amendments that specifies R&D projects that the US Government ordered and paid for. Note that in Pfizer’s case no R&D activities were ordered or paid for by the US Government, as these were excluded from the scope of contract.
- “Manufacturing” contract(s) that ordered a large scale manufacturing. This is different from Pfizer manufacturing contracts as the words “demonstration” and “prototype” are not used. I believe this is because OTA contracts must be for prototypes but FAR contracting doesn’t have to be.
Note on redactions. In both Moderna and Pfizer’s contracts many areas are redacted indicating a reason for redaction – the “redaction codes”. Redacted content has been given codes b (4) and b (6), standing for:
(b) (4) Disclosure of information that would affect the application of advanced technology in a U.S. weapons system,
and
(b) (6) Disclosure of information, including information of foreign governments, that would cause serious harm to relations between the United States and a foreign government or to ongoing diplomatic activities of the United States.
There are several versions of the contract available, plus amendments. The first version was signed on August 9, 2020 and the last available version is June 15, 2021. In one of them the name of the signatory on Moderna side was redacted with (b)(6). In another version it’s unredacted – it was Hamilton Bennett, a senior director of vaccine access and partnerships.
This 35 yo woman seems woefully underqualified, especially to “engineer the vaccine” as her role was described in the press. Moderna’s history is notable for high profile departures of competent and experienced people. Based on press reports and accounts of insiders, Stephan Bancel’s toxic management culture led to departures of many qualified scientists including heads of R&D, Oncology, Cardiovascular, Chemistry, Rare Diseases and even Vaccines (right around the time the company pivoted to vaccines in 2016). Terminal incompetence is a prerequisite for terminal fraud.
Unlike Pfizer’s and other covid countermeasures contracts, the Moderna contract is not under Other Transactions Authority (OTA) but FAR 43.103(a)(3) and “Mutual Agreement of the Parties”. This makes little difference with regard to the product liability and generally ignoring pharmaceutical regulations, as described below.
The total initial amount of contract was $1.5 billion, and this was increased to exactly $8,145,591,662.60 in later amendments. 60 cents – the criminals get points for style and attention to detail! Note that this is in addition to the $1B R&D contract for a handful of studies that didn’t matter which I discussed in Part 1.
The scope of the contract is “manufacturing of up to 500M doses”.
The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.
Note this is for “manufacturing” and not demonstration or prototype.
The Objectives:
This gets interesting. This paragraph includes feel-good sounding words which cover up the true intent: to declare an unrestricted bio-chemical-radiological and nuclear war on Americans, subvert consumer protections under the pretense of a “pandemic response”…
Read full story: Part 2 Moderna Contracts – by Sasha Latypova